Overview

Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

Status:
Recruiting
Trial end date:
2021-07-30
Target enrollment:
0
Participant gender:
All
Summary
Bortezomib considered the standard of care for treating multiple myeloma patients, we aimed to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Al-Rasheed University College
Collaborator:
Baghdad Medical City
Treatments:
Bortezomib
Cyclophosphamide
Dexamethasone
Lenalidomide
Criteria
Inclusion Criteria:

- Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A:
anemia, and B: bone lesions)

- Age above 18 years old

Exclusion Criteria:

- Age below 18 years

- Smoldering MM